Literature DB >> 31226034

Sham trials: benefits and risks for cardiovascular research and patients.

Marat Fudim1, Fatima Ali-Ahmed2, Manesh R Patel3, Paul A Sobotka4.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31226034     DOI： 10.1016/S0140-6736(19)31120-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Blood pressure and cardiac autonomic adaptations to isometric exercise training: A randomized sham-controlled study.

Authors:  Anthony Decaux; Jamie J Edwards; Harry T Swift; Philip Hurst; Jordan Hopkins; Jonathan D Wiles; Jamie M O'Driscoll
Journal:  Physiol Rep       Date:  2022-01

Review 2.  Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.

Authors:  Christopher J Czura; Marom Bikson; Leigh Charvet; Jiande D Z Chen; Manfred Franke; Marat Fudim; Eric Grigsby; Sam Hamner; Jared M Huston; Navid Khodaparast; Elliot Krames; Bruce J Simon; Peter Staats; Kristl Vonck
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

Review 3.  Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies.

Authors:  Ana Jorbenadze; Marat Fudim; Felix Mahfoud; Phillip B Adamson; Tarek Bekfani; Rolf Wachter; Horst Sievert; Piotr P Ponikowski; John G F Cleland; Stefan D Anker
Journal:  ESC Heart Fail       Date:  2021-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.